1. health and fitness
2. disease
3. diabetes

Diabetic Retinopathy
Treatment Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016
Future Market Insights
www.futuremarketinsights.com
sales@futuremarketinsights.com
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: hari.t@futuremarketinsights.com




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Diabetes is a chronic disorder associated with defects in the secretion of insulin from the
pancreas or hyperglycemia linked to insulin resistance which ultimately leads to long
term multi-organ complications of eye, kidneys, nerves, blood vessels and heart. The
most common and severe sight threatening complication of diabetes is Diabetic
Retinopathy (DR) with some form of DR present in around 25-33% diabetic persons at
any time. It leads to damaging of the blood vessels present in the retina of the eye. As
per WHO estimates, DR contributes around 4.8% of blindness globally. In the US, it is the
leading cause of vision loss and new-onset of blindness in working adults. At present
diabetes effects 336 million people worldwide which are projected to increase by 54% in
2030 and more than 75% among these diabetic for more than 20 years are likely to have
some form of diabetic retinopathy.
Diabetic Retinopathy Treatment Market: Drivers and Restraints
Diabetic Retinopathy affects both type 1 and type 2 diabetic patients and with prolific
increase in patient pool for both the indication, the market for diabetic retinopathy holds
great hopes. As per WHO, 41 percent of the population with diabetes are elderly hence
the growing market for diabetic retinopathy can be attributed to expanding geriatric
population size. In addition to this, up-gradation of healthcare infrastructure along with
the growing demand for early detection systems are some of the high impact rendering
drivers for the DR market. Also the clinical pipeline for DR seems full of promises with lots
of drug under umbrella specifically targeting diabetic retinopathy among the diabetic
patients.
Report
Description
Report Description
However, a dearth of skilled ophthalmologist combined with poor primary infrastructure
and lack of insurance facilities are restraining the growth of global diabetic retinopathy
market.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1322
Diabetic Retinopathy Treatment Market: Segmentation
Diabetic Retinopathy Treatment market is classified on the basis of Indication, Treatment
type, end users and geography.
Based on indication, the global diabetic retinopathy marketcan be segmented as follows:
• Non-Proliferative Diabetic Retinopathy (NPDR)
• Mild
• Moderate
• Severe
• Proliferative Diabetic Retinopathy (PDR)
Based on Treatment type, the global diabetic retinopathy marketcan be segmented as
follows:
• Anti-Vascular Endothelial Growth Factor (VEGF) drug
Report
Description
Report Description
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy
Based on end-user, the global diabetic retinopathy marketcan be segmented as follows:
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
Diabetic Retinopathy Treatment Market: Overview
According to WHO estimates, in 2012, 347 million people were suffering from diabetes
globally, of which 11% had diabetic retinopathy. This gigantic population size is expected
to increase further with a huge CAGR in coming years. Owing to improved infrastructure
and awareness among the people especially of emerging markets like China, India and
Brazil, there is strong emphasis on the quality of life (QALY) for diabetic patients
demanding early detection and treatment of chronic conditions such as Diabetic
Retinopathy, the market seems to be agile and open.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1322
Diabetic Retinopathy triples the chances of vision impairment and is linked to five-fold
risk of blindness.
Report
Description
Report Description
However, people suffering from DR can be treated most commonly with laser to prevent
visual impairment and blindness. However, there is a need for the development of lowcost, portable and easy to operate laser devices. Thus paying way to address various
unmet need in the diabetic retinopathy market which is expected to grow at great pace
in the coming 20 years.
Diabetic Retinopathy Treatment Market: Region-wise Outlook
Region wise, the global diabetic retinopathy treatment marketis classified into regions
namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific,
Japan, Middle East and Africa.Among all the geographies, North America dominated the
market followed by Europe. The factors attributable for North America is having high
obesity rates while Europe has large population of baby boomers. Asia is expected to
show the booming growth in next five years. Within the Asian region, western pacific
region account for greater share of blindness due to DR as compared to South-East Asia.
The major factor contributing to the rising share of Diabetic Retinopathy among the rising
economies are large pool of patients and rising support and funding provided by the
government. Under Rest of the World section Brazil is the largest market of diabetic
retinopathy.
Browse full report: http://www.futuremarketinsights.com/reports/diabetic-retinopathytreatment-market
Report
Description
Report Description
Diabetic Retinopathy Treatment Market: Key Players
The global Diabetic Retinopathy treatment market is dominated by Bayer AG, Pfizer Inc.,
Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant
Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., Ampio
Pharmaceuticals Inc., etc. Strategic acquisitions, geographic expansion, agreements, new
product launches and collaborations are the major adopted strategies by most key
players to achieve growth in the global Diabetic Retinopathy.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
sales@futuremarketinsights.com
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705